Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 12,245 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider David Bharucha sold 12,245 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $1.93, for a total transaction of $23,632.85. Following the transaction, the insider owned 99,848 shares of the company’s stock, valued at approximately $192,706.64. The trade was a 10.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

David Bharucha also recently made the following trade(s):

• On Monday, December 15th, David Bharucha sold 58,007 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.32, for a total transaction of $134,576.24.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock traded down $0.07 during trading on Wednesday, hitting $1.94. 1,697,941 shares of the company were exchanged, compared to its average volume of 3,110,069. Milestone Pharmaceuticals Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. The firm has a 50 day moving average price of $2.23 and a 200 day moving average price of $1.96. The stock has a market capitalization of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. On average, equities analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Propel Bio Management LLC raised its position in shares of Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after buying an additional 3,333,333 shares during the period. Orbimed Advisors LLC purchased a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $6,444,000. Simplify Asset Management Inc. lifted its stake in shares of Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after purchasing an additional 1,842,974 shares in the last quarter. Pathstone Holdings LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth about $2,000,000. Finally, Boxer Capital Management LLC acquired a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $1,333,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Analyst Upgrades and Downgrades

MIST has been the topic of several analyst reports. Wells Fargo & Company raised their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Zacks Research upgraded Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Milestone Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.